Peter Attia· MD
the phase 3 program is and the primary indication is respiratory infection or all infection respiratory tract infections and patient population is 65 and up 65 and up so the first study that we're calling the program the protector program the first one is fully enrolled 1024 patients they're getting 16 weeks of drug treatment and we're following them for respiratory tract infections with sort of an electronic record that the patients fill out if we were just targeting this at northern hemisphere patients is it your view that the optimal 16-week window would be sort of may june july august how are you deciding when winter cold and flu season is when they actually want to receive the drug yes okay so basically so you're so confident that 10 milligrams is not too high that you're willing to give them the drug during flu season or during winter cold season yes